

# Intellectual Property Prospector

## IP Assets Owned by Firms in Transition

March 5, 2007  
Volume 2, Number 10  
Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Atlantis Plastics, Inc.	<a href="#">07.0278</a>	Low Rating
Camera Platforms International, Inc.	<a href="#">07.0279</a>	Audit Concerns
China Aoxing Pharmaceutical Company, Inc.	<a href="#">07.0280</a>	Loss/Deficit
CV Therapeutics, Inc.	<a href="#">07.0281</a>	Loss/Deficit
Dermisonics, Inc.	<a href="#">07.0282</a>	Audit Concerns
DigiCorp	<a href="#">07.0283</a>	Loss/Deficit
Frezer, Inc.	<a href="#">07.0284</a>	Audit Concerns
GeM Solutions, Inc.	<a href="#">07.0285</a>	Audit Concerns
General Nutrition Centers, Inc.	<a href="#">07.0286</a>	Low Rating
IQ Micro, Inc.	<a href="#">07.0287</a>	Audit Concerns
Laurier International, Inc.	<a href="#">07.0288</a>	Audit Concerns
Lear Corporation	<a href="#">07.0289</a>	Loss/Deficit
Mera Pharmaceuticals, Inc.	<a href="#">07.0290</a>	Audit Concerns
Micro Imaging Technology, Inc.	<a href="#">07.0291</a>	Audit Concerns
Nektar Therapeutics	<a href="#">07.0292</a>	Loss/Deficit
Optimal Geomatics, Inc.	<a href="#">07.0293</a>	Loss/Deficit
Optime Therapeutics DE, Inc.	<a href="#">07.0294</a>	Bankruptcy
Orbit Brands Corporation	<a href="#">07.0295</a>	Audit Concerns
Owens-Illinois, Inc.	<a href="#">07.0296</a>	Low Rating
Paivis Corporation	<a href="#">07.0297</a>	Audit Concerns
Polypore, Inc.	<a href="#">07.0298</a>	Low Rating
Prevention Insurance.com	<a href="#">07.0299</a>	Audit Concerns
Protiva Biotherapeutics, Inc.	<a href="#">07.0300</a>	Involuntary Petition
Rival Technologies, Inc.	<a href="#">07.0301</a>	Audit Concerns
Royaltech Corporation	<a href="#">07.0302</a>	Audit Concerns
Sirius Satellite Radio, Inc.	<a href="#">07.0303</a>	Loss/Deficit
Star Gas Partners LP	<a href="#">07.0304</a>	Low Rating
Statmon Technologies Corporation	<a href="#">07.0305</a>	Loss/Deficit
Stoney Creek Technologies LLC	<a href="#">07.0306</a>	Bankruptcy
Sweet Success Enterprises, Inc.	<a href="#">07.0307</a>	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Telegen Corporation	<a href="#">07.0308</a>	Audit Concerns
TenFold Corporation	<a href="#">07.0309</a>	Audit Concerns
Univec, Inc.	<a href="#">07.0310</a>	Audit Concerns
US Biodefense, Inc.	<a href="#">07.0311</a>	Audit Concerns
Yacht Finders, Inc.	<a href="#">07.0312</a>	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

**Intellectual Property Prospector** identifies United States and Canadian companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

### **Prospector Profile Selection Criteria:**

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

**DISCLAIMER:** The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

**ACCURACY & COVERAGE:** The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

**SUBSCRIPTIONS:** Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

**Intellectual Property Prospector** is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector  
Profile  
07.0278**

**Atlantis Plastics, Inc.**

1870 The Exchange, Suite 200  
Atlanta, GA 30339  
(800) 497-7659

NAICS		326113
Employees		1,461
Revenue	(mil)	\$424.33
Income	(mil)	\$6.67
Assets	(mil)	\$238.91
Liability	(mil)	\$258.80
(for the year ended 12/31/2005)		

**Category:** Low Rating

**Event:** On February 26, 2007, Standard & Poor's Ratings Services lowered the corporate credit and senior secured ratings of Atlantis Plastics, Inc. to CCC+. The ratings agency also downgraded the credit rating to 'CCC+' and recovery rating to '3' to the Company's \$120 million term loan B bank loan due 2011 and \$25 million revolving credit facility bank loan due 2011. In addition, the credit and recovery ratings of the \$75 million junior secured term loan C bank due 2012 was downgraded to 'CCC-' and '5' respectively. The rating outlook is negative. Credit analyst Robyn Shapiro attributed the downgrades to the challenging industry conditions that led to a significant deterioration in credit metrics and continued cash flow generation.

**Intellectual Property:** The Company has registered various trademarks with the United States Patent and Trademark Office and certain overseas trademark regulatory agencies. The Company also has applications pending for the registration of patents and other trademarks. The Company believes that its trademark position is adequately protected in all markets it does business. The Company's plastic films segment produces certain stretch film products under non-exclusive licenses granted by ExxonMobil Corporation. [SEC Filing 10-K 03-31-06]

**Description:** The Company manufactures specialty and custom plastic products throughout the U.S. The Company operates three operating business segments: plastic films, injection molding and profile extrusion.

**Officers:** Earl W. Powell (Chair); Anthony F. Bova (Pres. & CEO); Paul G. Saari (SVP-Finance & CFO); Charles D. Murphy III (Dir.); Chester B. Vanatta (Dir.); Larry D. Horner (Dir.); Cesar Alvarez (Dir.); Jay Shuster (Dir.); Peter Vandenberg, Jr. (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol ATPL; NasdaqGM;  
8,255,823 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0279**

**Camera Platforms International, Inc.**

10909 Vanowen Street  
North Hollywood, CA 91605  
(818) 623-1700

NAICS		333315
Employees		2
Revenue	(mil)	\$0.34
Income	(mil)	(\$0.09)
Assets	(mil)	\$0.10
Liability	(mil)	\$2.37
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Rose, Snyder & Jacobs expressed doubts on Camera Platforms International, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has suffered recurring losses from operations, negative cash flows from operations, and has a net capital deficiency.

**Intellectual Property:** The Company has registered THE SHOTMAKER, AKELA, and ENLOUVA as trademarks in the United States, Canada, and Japan. [SEC Filing 10-K 02-20-07]

**Description:** The Company engages in the design, manufacture, rental, and lease of various production equipment to the motion picture, television, theatrical production, and music industries in the United States.

**Officers:** Martin Perellis (Pres., CEO, CFO & Dir.); William O. Fleischman (Dir.); Rick Hicks (Dir.)

**Auditor:** Rose, Snyder & Jacobs

**Securities:** Common Stock-Symbol CPFR.OB; OTC BB;  
23,740,964 common shares outstanding as of February 20, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0280**

<b>China Aoxing Pharmaceutical Company, Inc.</b> 444 Washington Boulevard, Unit 2424 Jersey City, NJ 07310 (201) 420-1076	NAICS	325412	
	Employees	186	
	Revenue	(mil)	\$0.00
	Income	(mil)	(\$1.51)
	Assets	(mil)	\$17.98
	Liability	(mil)	\$13.46
			(for the year ended 6/30/2006)

**Category:** Loss/Deficit

**Event:** China Aoxing Pharmaceutical Company, Inc. reported a \$1,021,218 net loss on \$345,907 of revenues for the second quarter ended Dec. 31, 2006, compared with a \$351,239 net loss on zero revenues for the same period a year ago. At Dec. 31, 2006, the Company's balance sheet showed \$31,025,074 in total assets, 15,114,461 in total liabilities, \$1,989,000 in convertible debentures, and \$13,921,613 in total stockholders' equity. The Company's balance sheet also showed strained liquidity with \$2,073,120 in total current assets available to pay \$10,883,861 in total current liabilities.

**Intellectual Property:** The Company has developed a patented manufacturing process for a variety of generic analgesic drugs, including Oxycodone, Pholcodine, Naloxone, and Tilidine. The Company is continuously designing and developing new technology. The Company relies on a combination of patents, trade secret laws, and restrictions on disclosure to protect intellectual property rights. [SEC Filing 10-KSB 10-13-06]

**Description:** The Company is engaged in the manufacture and distribution of analgesic drugs in the People's Republic of China.

**Officers:** Zhenjiang Yue (CEO, CFO & Dir.); John C. Leo (Sec. & Dir.)

**Auditor:** Paritz & Company PA

**Securities:** Common Stock-Symbol CAXG.OB; OTC BB;  
40,163,541 common shares outstanding as of February 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0281**

**CV Therapeutics, Inc.**

3172 Porter Dr.  
Palo Alto, CA 94304  
(650) 384-8500

NAICS		325414
Employees		746
Revenue	(mil)	\$36.79
Income	(mil)	(\$274.32)
Assets	(mil)	\$421.46
Liability	(mil)	\$467.25
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** CV Therapeutics, Inc. posted a net loss of \$274,320,000 on revenues of \$36,785,000 for the fiscal year 2006, as compared with a net loss of \$227,995,000 on revenues of \$18,951,000 for the fiscal year 2005. As of December 31, 2006, the Company's balance sheet showed \$45,798,000 in stockholders' deficit and \$1,086,874,000 in accumulated deficit.

**Intellectual Property:** The Company owns multiple patents and patent applications pending with the United States Patent and Trademark Office and foreign patent authorities relating to its technology. The Company has received issued patents claiming methods of using various sustained release formulations of ranolazine for the treatment of chronic angina. The Company also has a worldwide license from Roche to specified patents related to Ranexa. [SEC Filing 10-K 02-27-07]

**Description:** The Company is focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases.

**Officers:** Louis G. Lange (Chair & CEO); Daniel K. Spiegelman (CFO); Santo J. Costa (Dir.); Joseph M. Davie (Dir.); Thomas L. Gutshall (Dir.); Peter Barton Hutt (Dir.); Kenneth B. Lee, Jr. (Dir.); Barbara J. McNeil (Dir.); Thomas E. Shenk (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol CVTX; NasdaqGM;  
59,327,444 common shares outstanding as of February 21, 2007.  
2.0% senior subordinated convertible debentures due 2023; 2.75% senior subordinated convertible notes due 2012; 3.25% senior subordinated convertible notes due 2013.

[Return to top](#)

**Prospector  
Profile  
07.0282**

**Dermisonics, Inc.**

2 Park Plaza, Suite 450  
Irvine, CA 92614  
(949) 733-1101

NAICS		541710
Revenue	(mil)	\$0.00
Income	(mil)	(\$5.08)
Assets	(mil)	\$20.08
Liability	(mil)	\$4.47
(for the year ended 9/30/2006)		

**Category:** Audit Concerns

**Event:** Peterson Sullivan PLLC expressed doubts on Dermisonics, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. As a result of not yet generating significant revenues, the Company has experienced recurring losses and has liabilities in excess of liquid assets. In addition, the auditor notes that there are uncertainties relating to the Company's rights to the ownership of its significant intangible asset.

**Intellectual Property:** On July 28, 2004, the Company entered into an Asset Purchase Agreement with Encapsulation Systems, Inc. to acquire certain intellectual property encompassing patents filed with the United States Patent and Trademark Office and other proprietary technology and information. These patents cover a new type of non-invasive drug delivery system known as transdermal patch. [SEC Filing 10-KSB 02-16-07]

**Description:** The Company engages in the development of ultrasonic transdermal drug-delivery technologies.

**Officers:** Bruce H. Haglund (Chair & Dir.); Bruce K. Redding, Jr. (Dir.); Grant Atkins (Dir.)

**Auditor:** Peterson Sullivan PLLC

**Securities:** Common Stock-Symbol DMSIE.OB; OTC BB;  
49,224,005 common shares outstanding as of February 14, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0283**

**DigiCorp**

4143 Glencoe Avenue  
Marina Del Rey, CA 90292  
(310) 728-1450

NAICS		512120
Employees		14
Revenue	(mil)	\$0.33
Income	(mil)	(\$0.36)
Assets	(mil)	\$1.43
Liability	(mil)	\$0.83
(for the year ended 12/31/2005)		

**Category:** Loss/Deficit

**Event:** In its amended annual report for the year ended December 31, 2005, DigiCorp had a net loss of \$357,561 on revenues of \$334,110 during fiscal year 2005, higher than the net loss of \$37,643 on revenues of \$27,963 reported in fiscal 2004. As a result of recurring losses, the Company's balance sheet showed an accumulated deficit of \$397,862 as of December 31, 2005.

**Intellectual Property:** On February 7, 2006, the Company entered into an asset purchase agreement with Matthew B. Stuart under which it purchased several Internet domain names and all materials, intellectual property, goodwill and records, for: PerreoRadio.com, Radioperreo.com, Perreomobile.com, Perreotv.com, Puroperreo.com, Puroreggaeton.com, Purosandungueo.com, Sandungueoradio.com, Machetemusic.net, Machetemusic.org, Machetemusica.com and Musicamachete.com. [SEC Filing 10-K 02-23-07]

**Description:** The Company, through its wholly owned subsidiary, Rebel Crew Films, Inc., engages in the development, marketing, and distribution of programming content, multimedia technologies, and advertising via the Internet.

**Officers:** Jay Rifkin (CEO & Dir.); William B. Horne (CFO & Dir.); Philip Gatch (CTO); Alice M. Campbell (Dir.); Alan Morelli (Dir.); David M. Kaye (Dir.)

**Auditor:** Peterson & Co., LLP

**Securities:** Common Stock-Symbol DGCO.OB; OTC BB;  
46,506,200 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0284**

**Frezer, Inc.**

1010 University Avenue, Suite 40  
San Diego, CA 92103  
(619) 702-1404

NAICS		541710
Employees		3
Revenue	(mil)	\$0.00
Income	(mil)	(\$1.05)
Assets	(mil)	\$0.02
Liability	(mil)	\$0.11

(for the year ended 12/31/2006)

**Category:** Audit Concerns

**Event:** Armando C. Ibarra CPA raised doubts about the ability of Frezer, Inc. to continue as a going concern. The auditor notes that the Company has incurred losses since its inception and has not yet been successful in establishing profitable operations.

**Intellectual Property:** The Company is currently engaged in the research and development of its proprietary technology for a computer chip that can be used to provide a line of stem cells for research and development, called the "Cryo-Chip." The Company has also filed a U.S. provisional patent application for a "Multi-Well Cell Culture Plate" with the U.S. Patent and Trademark Office on August 22, 2006. [SEC Filing 10-KSB 02-23-07]

**Description:** The Company operates in the field of stem cell banking and regenerative medicine.

**Officers:** David R. Koos (Chair, Sec., CEO & CFO); Geoffrey O'Neill (Pres. & Dir.); Brian F. Pockett (COO & Dir.)

**Auditor:** Armando C. Ibarra CPA

**Securities:** Common Stock-Symbol FRZR.OB; OTC BB;  
15,534,064 common shares outstanding as of February 2, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0285**

**GeM Solutions, Inc.**

7935 Airport Pulling Road, Suite 201  
Naples, FL 34109  
(239) 592-1816

NAICS		541511
Employees		23
Revenue	(mil)	\$0.87
Income	(mil)	(\$5.08)
Assets	(mil)	\$2.18
Liability	(mil)	\$2.80

(for the year ended 6/30/2006)

**Category:** Audit Concerns

**Event:** Malone & Bailey PC raised substantial doubt about GeM Solutions, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has suffered recurring losses from operations and has negative working capital at June 30, 2006.

**Intellectual Property:** The Company has filed trademark registrations with the United States Patent and Trademark Office for GeM™, Global Ecommunications Management™, and GeM Solutions™. The Company does not have any patents relating to proprietary technologies, nor does it have any applications for such rights pending. The Company intends to apply for legal protection for certain of its intellectual property in the future. [SEC Filing 10-KSB/A 02-16-07]

**Description:** The Company, through its subsidiaries, provides content management software that enables organizations to block, monitor, filter, and archive eCommunications.

**Officers:** Mark G. Sampson (Chair, CEO & Treas.); Donald R. Innis (Pres.); John E. Baker (CFO & Sec.); Rusty Wright (SVP-Sales)

**Auditor:** Malone & Bailey PC

**Securities:** Common Stock-Symbol GEMI.OB; OTC BB;  
29,190,969 common shares outstanding as of October 10, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0286**

**General Nutrition Centers, Inc.**

300 Sixth Avenue  
Pittsburgh, PA 15222  
(412) 288-4600

NAICS		446191
Employees		4,870
Revenue	(mil)	\$1,317.71
Income	(mil)	\$18.67
Assets	(mil)	\$1,025.64
Liability	(mil)	\$684.76
(for the year ended 12/31/2005)		

**Category:** Low Rating

**Event:** On February 28, 2007, Moody's Investors Service had assigned a rating of Caa1, LGD5, 77%, to General Nutrition Centers, Inc.'s \$300 million floating-rate seven-year senior notes and a rating of Caa2, LGD6, 95%, to the \$125 million fixed-rate eight-year senior subordinated notes. The proceeds of the debt instruments will be used to finance the leverage buyout of the Company from Apollo Management.

**Intellectual Property:** The Company believes trademark protection is particularly important to the maintenance of its recognized brand names. The Company owns or has rights to material trademarks or trade names used in conjunction with the sale of its products, including the GNC brand name. The Company also relies upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain its competitive position. The Company also is a party to several intellectual property license agreements relating to certain of its products. [SEC Filing 10-K 03-10-06]

**Description:** The Company is a global specialty retailer of nutritional supplements, which include sports nutrition products, diet products, VMHS (vitamins, minerals and herbal supplements) and specialty supplements.

**Officers:** Robert J. DiNicola (Chair); Joseph Fortunato (Pres. & CEO); Robert Homler (EVP & COO); Curtis J. Larrimer (EVP & CFO); Lee Karayusuf (SVP-Distribution & Transportation); Michael Locke (SVP-Manufacturing); Darryl Green (SVP-Domestic Franchising); Reginald N. Steele (SVP-Int'l. Franchising); Susan Trimbo (SVP-Scientific Affairs); Tom Dowd (SVP); Laurence M. Berg (Dir.); Peter P. Copses (Dir.); George G. Golleher (Dir.); Joseph W. Harch (Dir.); Andrew S. Jhawar (Dir.); Edgardo A. Mercadante (Dir.)

**Auditor:** PricewaterhouseCoopers LLP

**Securities:** 100 common shares outstanding as of October 27, 2006.  
8-5/8% senior notes due 2011; 8-1/2% senior subordinated notes due 2010.

[Return to top](#)

**Prospector  
Profile  
07.0287**

**IQ Micro, Inc.**

500 Australian Ave., Suite 700  
West Palm Beach, FL 33401  
(561) 514-0118

NAICS 533110

Revenue	(mil)	\$0.00
Income	(mil)	(\$1.50)
Assets	(mil)	\$0.41
Liability	(mil)	\$1.91

(for the year ended 9/30/2006)

**Category:** Audit Concerns

**Event:** Daszkal Bolton LLP raised doubts on IQ Micro, Inc.'s ability to continue as a going concern, noting that the Company has no revenue and is dependent on external financing to fund operations.

**Intellectual Property:** On January 12, 2006, Osmotex AS and Osmotex USA, Inc., entered into a Technology License Agreement with the Company, under which they licensed exclusive, worldwide sales and marketing rights to microfluidics technology developed and patented by Osmotex, as well as additional intellectual property rights. [SEC Filing 10-KSB 02-16-07]

**Description:** The Company was established to commercialize technology developed by Osmotex AS, a Norwegian company incorporated in 1999. Osmotex's technology precisely controls the movement of fluids on a micro scale.

**Officers:** Svein Milford (Chair); Johnny Christiansen (Pres., CEO & Dir.); Robert Rudman (CFO, Sec., Treas. & Dir.); Trond Eidsnes (Dir.)

**Auditor:** Daszkal Bolton LLP

**Securities:** Common Stock-Symbol IQMC.OB; OTC BB;  
7,529,500 common shares outstanding as of February 12, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0288**

**Laurier International, Inc.**

101-1870 Parkinson Way, Kelowna  
British Columbia V1Y 8C9 Canada  
(250) 712-9354

NAICS	541370		
Revenue	(mil)	\$0.00	
Income	(mil)	(\$0.02)	
Assets	(mil)	\$0.00	
Liability	(mil)	\$0.05	
(for the year ended 12/31/2006)			

**Category:** Audit Concerns

**Event:** Chang Park raised concerns on Laurier International, Inc.'s ability to continue as a going concern due to the Company's continued losses from operations.

**Intellectual Property:** Despite the fact that the Company's Geotheatre products produce a visually physical environment in the schoolyard, they are not a structure or thing and therefore do not fall under patent laws. However, they are written descriptive materials as might be found in a 'how-to' publication and therefore fall under the copyright laws. For example, the Geotheatre written learning resources obtain copyright protection as "original works of authorship" under the category "literary works"; while the Maps and Plans created by the Geotheatre instructions fall under the category "pictorial, graphic and sculptural works". [SEC Filing 10-KSB 02-15-07]

**Description:** The Company supplies products that fill a market niche within the education industry primarily in the Social Studies area focusing on Geography.

**Officers:** John Bracey (Pres., CEO, CFO, Sec., Treas. & Dir.); Katherine E. Bracey (Dir.)

**Auditor:** Chang Park

**Securities:** Common Stock-Symbol LRNL.OB; OTC BB;  
5,501,000 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0289**

**Lear Corporation**

21557 Telegraph Road  
Southfield, MI 48034  
(248) 447-1500

NAICS		336360
Employees		104,000
Revenue	(mil)	\$17,838.90
Income	(mil)	(\$707.50)
Assets	(mil)	\$7,850.50
Liability	(mil)	\$7,248.50
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Lear Corporation's net loss for the year ended Dec. 31, 2006, decreased to \$707.5 million from \$1,381.5 million in the year ended Dec. 31, 2005, reflecting loss on divestiture of the Company's interior business of \$636 million in 2006 and goodwill impairment charges of \$1.0 billion in 2005. Net sales for the year ended Dec. 31, 2006, increased by 4.4%, or \$750 million, to \$17,838.9 million from \$17,089.2 million in 2005. The Company's balance sheet at Dec. 31, 2006, showed total assets of \$7,850.5 million, total liabilities of \$7,248.5 million, and total stockholders' equity of \$602.0 million. Lear's total stockholders' equity at Dec. 31, 2005, was \$1,111.0 million.

**Intellectual Property:** The Company holds many patents and patent applications pending worldwide. While the patent portfolio is a valuable asset, no individual patent or group of patents is critical to the success of its business. The Company also licenses selected technologies to automotive manufacturers and to other automotive suppliers. The Company has numerous registered trademarks in the United States and in many foreign countries. The most important of these marks include "LEAR CORPORATION" and "LEAR", which are widely used in connection with its product lines and services. The trademarks and service marks "ADVANCE RELENTLESSLY," "CAR2U," "INTELLITIRE," "PROTEC," "PROTEC PLUS" and others are also used in connection with certain product lines and services. [SEC Filing 10-K 02-27-07]

**Description:** The Company provides automotive interior systems worldwide. It has three segments: Seating; Interior; and Electronic and Electrical.

**Officers:** Robert E. Rossiter (Chair & CEO); James H. Vandenberghe (Vice Chair & CFO); Daniel A. Ninivaggi (EVP, Sec. & Gen. Counsel); Douglas G. DelGrosso (Pres. & COO); James M. Brackenbury (SVP); Roger A. Jackson (SVP-HR); Raymond E. Scott (SVP); Matthew J. Simoncini (SVP-Fin.); Shari L. Burgess (VP & Treas.); James L. Murawski (VP & Controller)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol LEA; NYSE;  
76,387,448 common shares outstanding as of February 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0290**

**Mera Pharmaceuticals, Inc.**

73-4460 Queen Kaahumanu Highway  
Kailua-kona, HI 96740  
(808) 326-9301

NAICS	541710
Employees	5
Revenue (mil)	\$0.39
Income (mil)	(\$0.51)
Assets (mil)	\$2.43
Liability (mil)	\$0.44
(for the year ended 10/31/2006)	

**Category:** Audit Concerns

**Event:** Jewett Schwartz Wolfe & Associates expressed doubts on Mera Pharmaceuticals, Inc.'s ability to continue as a going concern. The auditor cited the Company's need to seek new sources or methods of financing or revenue to pursue its business strategy.

**Intellectual Property:** The Company develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. The Company has been awarded or has filed applications for roughly a dozen patents relating to various processes, including the process and apparatus for the production of photosynthetic microbes and the method of control of microorganism growth processes. [SEC Filing 10-KSB 02-14-07]

**Description:** The Company engages in the development and commercialization of natural products from microalgae using its Mera Growth Module photobioreactor technology.

**Officers:** Gregory F. Kowal (CEO, Sec. & Dir.); Sonolynne N. Flores (VP & GM); Kenneth Crowder (Dir.); Daniel P. Beharry (Dir.)

**Auditor:** Jewett Schwartz Wolfe & Associates

**Securities:** Common Stock-Symbol MRPI.OB; OTC BB;  
493,480,710 common shares outstanding as of October 31, 2006.

[Return to top](#)



**Prospector  
Profile  
07.0291**

**Micro Imaging Technology, Inc.**

970 Calle Amanecer, Suite F  
San Clemente, CA 92673  
(949) 485-6006

NAICS		541710
Employees		5
Revenue	(mil)	\$0.00
Income	(mil)	(\$3.80)
Assets	(mil)	\$0.14
Liability	(mil)	\$2.66
(for the year ended 10/31/2006)		

**Category:** Audit Concerns

**Event:** Hein & Associates LLP expressed doubt on Micro Imaging Technology, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor points out that the Company has recurring losses from operations, which has resulted in an accumulated deficit of \$27,809,201 as of October 31, 2006.

**Intellectual Property:** In July 2002, the Company was granted U.S. Patent No. 6,639,672 on its rapid microbe detection technology. The Company also received a U.S. continuation-in-part patent on this technology on October 28, 2003. Corresponding foreign patents are pending in Europe, Australia, Mexico and Japan. [SEC Filing 10-KSB 02-15-07]

**Description:** The Company engages in the research and development of a nonbiological identification method and process for the detection and identification of pathogenic microbes.

**Officers:** Michael W. Brennan (Chair & CEO); George R. Farquhar (COO); Catherine Patterson (CFO & Sec.); Ralph W. Emerson (Dir.); Victor A. Hollander (Dir.)

**Auditor:** Hein & Associates LLP

**Securities:** Common Stock-Symbol MMTC.OB; OTC BB;  
16,041,026 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0292**

**Nektar Therapeutics**

150 Industrial Rd.  
San Carlos, CA 94070  
(650) 631-3100

NAICS		325412
Employees		777
Revenue	(mil)	\$217.72
Income	(mil)	(\$154.76)
Assets	(mil)	\$768.18
Liability	(mil)	\$541.12
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Nektar Therapeutics posted a net loss of \$38,855,000 on revenues of \$69,904,000 for the fourth quarter ended December 31, 2006, as compared with a net loss of \$108,102,000 on revenues of \$32,881,000 for the same quarter in 2005. The Company's balance sheet showed \$1,056,993,000 in accumulated deficit and \$227,060,000 in stockholders' equity as of December 31, 2006.

**Intellectual Property:** The Company's patent portfolio contains patents and patent applications that encompass each of its technologies including Pulmonary Technology and PEGylation Technology platforms. As of December 31, 2006, the Company owns over 1,000 U.S. and foreign patents and a number of patent applications that cover various aspects of its technologies or products. The Company's PEGylation Technology patents and patent applications cover reactive PEG derivatives, PEG-drug conjugates, PEG-based pro-drugs and PEG-drug delivery vehicles. The Pulmonary Technology patents and patent applications cover compositions and methods and apparatus for preparing, packaging, and delivering particles for pulmonary delivery of both large and small molecule drugs. [SEC Filing 10-K 03-01-07]

**Description:** The Company provides a portfolio of drug delivery technologies that improve the performance of molecules and drug delivery.

**Officers:** Howard W. Robin (Pres., CEO, & Dir.); Louis Drapeau (SVP-Finance & CFO); John S. Patton (Chief Scientific Officer & Dir.); David Johnston (SVP-Research & Development); Nevan C. Elam (SVP-Corporate Operations, Gen. Counsel, & Sec.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock Symbol NKTR; NasdaqGS;  
91,397,227 common shares outstanding as of February 1, 2007.  
5% notes due February 2007; 3.5% notes due October 2007; 3.25% notes due September 2012

[Return to top](#)

**Prospector  
Profile  
07.0293**

**Optimal Geomatics, Inc.**

625 West Kent Avenue, Vancouver  
British Columbia V6P 6T7 Canada  
(604) 654-1850

NAICS	541511		
Employees			
Revenue	CDN(mil)	\$16.49	
Income	CDN(mil)	(\$1.26)	
Assets	CDN(mil)	\$12.85	
Liability	CDN(mil)	\$6.09	
(for the year ended 10/31/2006)			

**Category:** Loss/Deficit

**Event:** Optimal Geomatics Inc. reported a net loss of CDN\$1.2 million on CDN\$16 million of revenues for the fiscal year ended Oct. 31, 2006, compared to a net income of CDN\$1.2 million on CDN\$10 million of revenues in 2005. The Company's balance sheet for 2006 showed CDN\$12.8 million in total assets, and CDN\$30 million in total liabilities, resulting in a \$17.2 million stockholders' deficit.

**Intellectual Property:** The Company relies on a combination of copyright and trade secret laws, confidentiality procedures, contract provisions and other measures to protect its proprietary information. The Company also licenses and uses software from third parties in its business. During 2006, the Company launched geoPylot, a proprietary software for asset data management and viewing of imagery supplied to its energy customers. [Annual Report October 31, 2006]

**Description:** The Company specializes in the science and technology of gathering, analyzing, interpreting, distributing and using geographic information.

**Officers:** WP Roger Bannon (Chair); Colum Caldwell (Pres., CEO & Dir.); Verne Pecho (CFO); Dr. Dmitri Rosenrauch (CTO); Greg Peet (Dir.); Nizar Somji (Dir.); Erik Dysthe (Dir.)

**Auditor:** Grant Thornton LLP

**Securities:** Common Stock-Symbol OPG.V; CDNX;  
52,512,123 common shares outstanding as of October 31, 2006.

[Return to top](#)

***Prospector  
Profile  
07.0294***

**Optime Therapeutics DE, Inc.**

P.O. Box 6279  
San Rafael, CA 94903  
(415) 472-4623

NAICS

541710

**Category:** Bankruptcy

**Event:** Optime Therapeutics DE, Inc. filed for Chapter 11 protection on February 6, 2007 with the Bankruptcy Court for the Northern District of California, case number 07-10129, before Judge Alan Jaroslovsky.

**Intellectual Property:** The Company has developed a patented drug delivery technology called OPTISOMES™, which is based on the novel, topical use of liposomes. The Company also has patented a manufacturing technology called OPTIMIX™, which allows for the consistent and cost-effective production of its products at commercial scale. [Company Website]

**Description:** The Debtor is a research-based pharmaceutical Company.

**Officers:** John Kinzell (Officer)

**Attorneys:** Craig Stuppi, Esq. of Law Offices of Stuppi and Stuppi; Walnut Creek, CA; (415) 786-4465

**Notes:** The Company listed estimated assets and debt of \$1 million to \$100 million when it filed for bankruptcy.

[Return to top](#)

**Prospector  
Profile  
07.0295**

**Orbit Brands Corporation**

13701 Riverside Drive, Suite 701  
Sherman Oaks, CA 91423  
(818) 501-2238

NAICS		517212
Employees		1
Revenue	(mil)	\$0.00
Income	(mil)	(\$31.42)
Assets	(mil)	\$0.01
Liability	(mil)	\$35.18
(for the year ended 12/31/2004)		

**Category:** Audit Concerns

**Event:** Malone & Bailey PC raised doubts on Orbit Brands Corporation's ability to continue as a going concern due to its recurring losses from operations and working capital deficiency.

**Intellectual Property:** Effective June 30, 2004, the Company acquired Malibu Beach Beverage Group LLC, including its rights, title and interests in all intellectual property of low carb beverages. The Company's Floating Bed International, Inc. subsidiary develops, markets and sells patent-pending high quality rest and relaxation devices in the form of beds and hammocks. [SEC Filing 10-KSB 02-14-07]

**Description:** The Company, through its wholly owned subsidiaries, provides telephony services to individual customers and small businesses. Three creditors filed an involuntary chapter 11 petition against the Company on June 25, 2004 with the Bankruptcy Court for the Central District of California, case number 04-24171.

**Officers:** Joseph R. Cellura (Chair & CEO); Denise Bertolini (Sec. & Dir.)

**Auditor:** Malone & Bailey PC

**Securities:** Common Stock-Symbol OBBCQ.PK; PNK;  
3,094,350,600 common shares outstanding as of June 13, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0296**

**Owens-Illinois, Inc.**

One Michael Owens Way  
Perrysburg, OH 43551  
(419) 247-5000

NAICS		327213
Employees		28,000
Revenue	(mil)	\$7,523.50
Income	(mil)	(\$27.50)
Assets	(mil)	\$9,320.70
Liability	(mil)	\$8,964.00
(for the year ended 12/31/2006)		

**Category:** Low Rating

**Event:** Fitch Ratings has affirmed the rating of ‘CCC+/RR5’ for the senior unsecured notes and ‘CCC/RR6’ for the preferred stock of Owens-Illinois, Inc. Fitch’s rating actions are supported by the Company’s leading market positions, global footprint, technology leadership, and long-term customer relationships with large, stable customers. The rating outlook is stable.

**Intellectual Property:** The Company has a number of intellectual property rights, comprised of both patented and proprietary technology, that make its glass forming machines more efficient and productive than those used by competitors. In addition, the efficiency of the Company’s glass forming machines is enhanced by the Company’s overall approach to cost efficient manufacturing technology, which extends from batch house to warehouse. This technology is proprietary to the Company through a combination of issued patents, pending applications, copyrights, trade secret and proprietary know-how. [SEC Filing 10-K 03-01-07]

**Description:** The Company manufactures and markets packaging products worldwide. It operates through two segments, Glass Containers and Plastics Packaging.

**Officers:** Albert P. L. Stroucken (Chair, Pres., & CEO); Edward C. White (SVP & CFO); James W. Baehren (SVP-Strategic Planning & Gen. Counsel); John Bachey (VP-Global Accounts Management); Gerard D. Doyle (VP & CIO); Raymond C. Schlaff (VP & Chief Procurement Officer); Robert E. Lachmiller (VP-Glass Container Research & Development); Stephen P. Malia (SVP & Chief Human Resource Officer); Stephen P. Bramlage (VP & Treas.); Philip McWeeny (VP & Gen. Counsel)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock Symbol NYSE; OI;  
154,432,537 common shares outstanding as of January 31, 2007.  
8.875% senior secured due notes 2009; 7.75% senior secured notes due 2011; 8.75% senior secured notes due 2012; 8.10% senior secured notes due 2007; 7.35% senior notes due 2008; 8.25% senior notes due 2013; 6.75% senior notes due 2014; 7.50% senior debentures due 2010; 7.80% senior debentures due 2018; 9.25% senior subordinated notes due 2009.

[Return to top](#)

**Prospector  
Profile  
07.0297**

**Paivis Corporation**

3475 Lenox Road, Suite 400  
Atlanta, GA 30326  
(404) 601-2885

NAICS		446199
Employees		9
Revenue	(mil)	\$6.90
Income	(mil)	(\$4.09)
Assets	(mil)	\$6.87
Liability	(mil)	\$7.62

(for the year ended 9/30/2006)

**Category:** Audit Concerns

**Event:** Jaspers + Hall, PC raised doubts on Paivis Corporation's ability to continue as a going concern after auditing the Company's financial statements. The auditor points out that the Company has recurring losses from operations and difficulties in generating sufficient cash flow to meet obligations and sustain operations.

**Intellectual Property:** The Company relies on a combination of patents, copyrights, trademarks, domain name registrations and trade secret laws in the United States and other jurisdictions and contractual restrictions to protect intellectual property rights and brand names. [SEC Filing 10-KSB 02-22-07]

**Description:** The Company is a facility-based wholesale telecommunications carrier that delivers many application/value-added services within the prepaid services space.

**Officers:** Gregory L. Bauer (Pres., CEO, Int. CFO & Dir.); Guriqbal Randhawa (Dir.)

**Auditor:** Jaspers + Hall, PC

**Securities:** Common Stock-Symbol PAVCE.OB; OTC BB;  
30,558,352 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0298**

**Polypore, Inc.**

13800 South Lakes Drive  
Charlotte, NC 28273  
(704) 588-5310

NAICS		325211
Employees		1,800
Revenue	(mil)	\$432.50
Income	(mil)	\$14.02
Assets	(mil)	\$1,363.34
Liability	(mil)	\$1,052.06
(for the year ended 12/31/2006)		

**Category:** Low Rating

**Event:** On February 27, 2007, Moody's Investors Service has affirmed its ratings of Caa1, LGD4, 65% to both of Polypore, Inc.'s U.S. dollar and Euro guaranteed senior subordinated notes due May 2012. Moody's also affirmed its Caa2, LGD6, 91% rating on the Company's \$300 million of 10.5% unguaranteed senior discount notes due October 2012. The ratings reflect the Company's high leverage and weak interest coverage metrics which are consistent with a low speculative grade rating.

**Intellectual Property:** The Company considers patents, patent licenses and trademarks to be important to its business. The Company seeks to protect this proprietary know-how through United States and foreign patent and trademark registrations. In addition, the Company maintains certain trade secrets for which it has not sought patent protection, in order to maintain the confidentiality of such trade secrets. [SEC Filing 10-K 03-31-06]

**Description:** The Company, a subsidiary of Polypore International, Inc., develops, manufactures, and markets highly specialized polymer-based membranes used in separation and filtration processes.

**Officers:** Michael Graff (Chair); Frank Nasisi (Vice Chair); Robert B. Toth (Pres., CEO, & Dir.); Lynn Amos (CFO, Treas., & Sec.); David A. Barr (Dir.); Kevin Kruse (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** 100 common shares outstanding as of November 14, 2006 owned by Polypore International, Inc.

[Return to top](#)



**Prospector  
Profile  
07.0299**

**Prevention Insurance.com**  
2770 South Maryland Parkway  
Las Vegas, NV 89109  
(702) 732-2758

NAICS	550000		
Revenue	(mil)	\$0.16	
Income	(mil)	(\$0.07)	
Assets	(mil)	\$0.00	
Liability	(mil)	\$0.01	
(for the year ended 4/30/2006)			

**Category:** Audit Concerns

**Event:** Beadle, McBride, Evans & Reeves, LLP raised doubts on Prevention Insurance.com's ability to continue as a going concern due to its lack of continuing source of revenue.

**Intellectual Property:** The Company owns the newly developed Prevention Insurance website and the ownership rights in the trademarks for Nutra-Prevention and Nutra-Protection formulas. These formulations emphasize health maintenance by providing multiple vitamins and a wide range of additional nutritional supplements for daily consumption. [SEC Filing 10-KSB/A 02-14-07]

**Description:** The Company intends to organize independent insurance agencies to create a co-operative group of health, life, and casualty insurance companies in the United States.

**Officers:** Scott C. Goldsmith (Pres. & CEO); George T. Nasser (Dir.)

**Auditor:** Beadle, McBride, Evans & Reeves, LLP

**Securities:** Common Stock-Symbol PVNC.OB; OTC BB;  
19,719,362 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0300****Protiva Biotherapeutics, Inc.**

100-3480 Gilmore Way, Burnaby  
British Columbia V5G 4W7 Canada  
(604) 630-5061

NAICS

541710

**Category:** Involuntary Petition

**Event:** Inex Pharmaceuticals Corporation has submitted a petition for filing in the Supreme Court of British Columbia seeking to have Protiva Biotherapeutics, Inc. declared bankrupt and that a bankruptcy order be made in respect of the property of Protiva. Under agreements between INEX and Protiva, Protiva is to reimburse INEX for certain patent costs incurred by INEX. However, Protiva has not paid INEX since June 2006. The total amount owed to INEX from July 2006 to December 2006 is \$71,882.89, not including interest. INEX has been told that there are other creditors of Protiva whose invoices have not been paid when due.

**Intellectual Property:** The Company's proprietary Stable Nucleic-Acid Lipid Particle (SNALP) technology is an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), aptamers, and plasmid DNA, to target cells. It represents a breakthrough in the field of RNA interference. The Company owns or holds exclusive rights to 14 issued U.S. patents pertaining to SNALP technology. Each patent family consists of numerous corresponding continuations, divisional applications, issued foreign patents and/or pending applications. The Company's portfolio includes an additional 15 new patent applications with pending U.S. and foreign cases. [Company Website]

**Description:** The Company is focused on the development of nucleic acid based pharmaceutical products to fight serious human diseases, such as cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections.

**Officers:** Mark J. Murray, Ph.D. (Pres. & CEO); Ian MacLachlan, Ph.D. (Chief Scientific Officer); Donald Jewell (Dir.); Ronald S. Whitehead (Dir.); Dr. Michael J. Abrams (Dir.); Pat Brady (Dir.); R. Ian Lennox (Dir.)

**Notes:** There is no public trading market for the Company's common stock.

[Return to top](#)

**Prospector  
Profile  
07.0301**

**Rival Technologies, Inc.**

3155 East Patrick Lane, Suite 1  
Las Vegas, NV 89120  
(888) 989-0584

NAICS 324110

Revenue	(mil)	\$0.00
Income	(mil)	(\$1.41)
Assets	(mil)	\$0.77
Liability	(mil)	\$0.11

(for the year ended 12/31/2005)

**Category:** Audit Concerns

**Event:** Dohan and Company, CPAs, P.A. expressed doubt on Rival Technologies, Inc.'s ability to continue as a going concern due to the Company's recurring losses from operations, resulting in an accumulated deficit of approximately \$14,300,354 as of December 31, 2005.

**Intellectual Property:** In May 2005, the Company filed a patent application with the United States Patent and Trademark Office for the Continuous Water Injection (CWI) technology systems and process. The CWI technology was acquired from M.A. Turbo/Engine Ltd in 2003. The CWI technology is designed to reduce harmful nitrogen oxide and smoke emissions, improve fuel efficiency and provide cleaner operations of diesel engines. [SEC Filing 10-KSB 02-22-07]

**Description:** The Company engages in the acquisition and development of technologies related to diesel engines, and oil and gas in Canada and the United States.

**Officers:** Robin J. Harvey (Pres., Sec., Treas., CFO & Dir.)

**Auditor:** Dohan and Company, CPAs, P.A.

**Securities:** Common Stock-Symbol RVTI.PK; PNK;  
46,506,200 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0302**

**Royaltech Corporation**

1855 Talleyrand, Brossard  
Quebec J4W 2Y9 Canada  
(514) 586-3168

NAICS 541710

Revenue	(mil)	\$0.00
Income	(mil)	(\$0.22)
Assets	(mil)	\$0.09
Liability	(mil)	\$0.01

(for the year ended 9/30/2006)

**Category:** Audit Concerns

**Event:** Manning Elliott LLP raised doubts on Royaltech Corp.'s ability to continue as a going concern because the Company has not generated revenue and has accumulated losses since inception.

**Intellectual Property:** The Company has obtained the non-exclusive right to manufacture and market four clinical diagnostic techniques/kits which were developed by Mr. Kang Zhang after years of research and development. These techniques/kits have been approved by the Chinese government after a series of clinical testing and meet the regulations of various Chinese State agencies. The Company also has the first right to manufacture and market any future products that are currently under development. [SEC Filing 10-KSB 02-15-07]

**Description:** The Company is primarily engaged in the business of developing, manufacturing and marketing innovative biotech products that are applied in medical diagnosis.

**Officers:** Chenxi Shi (Pres., CEO & Dir.); Victor I. H. Sun (VP & Dir.); Chun Xu (VP & Dir.)

**Auditor:** Manning Elliott LLP

**Securities:** 15,023,800 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0303**

**Sirius Satellite Radio, Inc.**

1221 Ave. of the Americas, 36th Fl.  
New York, NY 10020  
(212) 584-5100

NAICS		515112
Employees		614
Revenue	(mil)	\$637.24
Income	(mil)	(\$1,104.87)
Assets	(mil)	\$1,658.53
Liability	(mil)	\$2,047.60
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Sirius Satellite Radio, Inc. posted a net loss of \$245,597,000 on revenues of \$193,380,000 for the quarter ended December 31, 2006, as compared with a net loss of \$311,389,000 on revenues of \$80,004,000 for the same quarter in 2005. As of December 31, 2006, the Company's balance sheet showed stockholders' deficit of \$389,071,000 and accumulated deficit of \$3,833,720,000. The Company also had \$1,658,249,000 in total assets and \$2,047,599,000 in total liabilities.

**Intellectual Property:** The Company has several registrations and approved applications in the U.S. Patent and Trademark Office for the "SIRIUS" trademark and the "Dog Design" logo used in connection with its products and service. In connection with music programming, the Company must negotiate and enter into royalty arrangements with two sets of rights holders: holders of copyrights in musical works, or songs, and holders of copyrights in sound recordings. [SEC Filing 10-K 03-01-07]

**Description:** The Company broadcasts digital-quality audio from three orbiting satellites throughout the continental U.S.

**Officers:** Joseph P. Clayton (Chair); Mel Karmazin (CEO & Dir.); David J. Frear (EVP & CFO); Adrienne Calderone (SVP & Controller); Leon D. Black (Dir.); Lawrence F. Gilberti (Dir.); James P. Holden (Dir.); Warren N. Lieberfarb (Dir.); Michael J. McGuinness (Dir.); James F. Mooney (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol SIRI; NasdaqNM;  
1,406,255,531 common shares outstanding as of November 3, 2006.  
9-5/8% senior notes due 2013; 3-1/4% convertible notes due 2011; 2-1/2% convertible notes due 2009; 3-1/2% convertible notes due 2008; 8-3/4% convertible subordinated notes due 2009.

[Return to top](#)

**Prospector  
Profile  
07.0304**

**Star Gas Partners LP**

2187 Atlantic Street  
Stamford, CT 06902  
(203) 328-7310

NAICS		424710
Employees		2,610
Revenue	(mil)	\$1,296.51
Income	(mil)	(\$54.26)
Assets	(mil)	\$581.21
Liability	(mil)	\$407.88
(for the year ended 9/30/2006)		

**Category:** Low Rating

**Event:** On February 28, 2007, Moody's Investors Service changed Star Gas Partners LP's outlook from negative to stable and affirm the Company's 'Caa1' corporate family rating and probability of default rating. The ratings agency also affirmed the Caa3, LGD5, 85%, rating on the Company's \$174 million non-guaranteed 10.25% senior unsecured notes. Senior analyst Pete Speer said that the ratings reflect the continued challenges the Company faces in growing its customer base through continued reductions in customer attritions and acquisitions.

**Intellectual Property:** The Company markets its products and services under various trademarks, including Petro and Meenan. The Company believes that the Petro, Meenan and other trademarks and service marks are an important part of its ability to attract new customers and to effectively maintain and service its customer base. [SEC Filing 10-K 01-17-07]

**Description:** The Company operates as a home heating oil distributor and services provider in the U.S.

**Officers:** Paul A. Vermynen, Jr. (Chair); Joseph P. Cavanaugh (CEO & Dir.); Daniel P. Donovan (Pres., COO, & Dir.); Richard G. Oakley (VP & Controller); Richard F. Ambury (CFO); Henry D. Babcock (Dir.); C. Scott Baxter (Dir.); Bryan H. Lawrence (Dir.); Sheldon B. Lubar (Dir.); William P. Nicoletti (Dir.)

**Auditor:** KPMG LLP

**Securities:** Common Stock Symbol SGU; NYSE;  
76,100,065 common shares outstanding as of January 31, 2007.  
10.25% senior notes due 2013

[Return to top](#)

**Prospector  
Profile  
07.0305**

**Statmon Technologies Corporation**

345 North Maple Drive, Suite 120  
Beverly Hills, CA 90210  
(310) 288-4580

NAICS		541511
Employees		12
Revenue	(mil)	\$1.26
Income	(mil)	(\$3.04)
Assets	(mil)	\$0.42
Liability	(mil)	\$5.07
(for the year ended 6/30/2006)		

**Category:** Loss/Deficit

**Event:** In its quarterly financial statements for the three-month period ended Dec. 31, 2006, Statmon Technologies Corp.'s balance sheet showed \$1,302,092 in total assets, \$5,929,996 in total liabilities, resulting in a \$4,627,904 stockholders' deficit. At June 30, 2006, the Company's stockholders' deficit stood at \$5,166,336. The Company disclosed that it has incurred net losses of approximately \$11,566,000 since its inception and has net working capital deficiency of approximately \$4,899,000 at Dec. 31, 2006. In addition, it has not been current in the payment of its Federal, State and Local payroll taxes.

**Intellectual Property:** The Company has designed its software products for use with personal computers and devices running in the Microsoft Windows operating environment. The Company relies on internally developed computer code, new technologies and know-how to help protect its intellectual property. The Company regards its technology as proprietary and attempts to protect it by implementing security password codes and encryption. The Company has trademark protection for the name on its products and intends to apply for registration of certain copyrights and key trademarks and service marks. The Company also intends to introduce new trademarks and service marks. The Company has not applied for nor does it hold any patents on any of its products. [SEC Filing 10-KSB 07-14-06]

**Description:** Statmon Technologies Corp. engages in the development, marketing, and licensing of monitoring and remote control software and integration products.

**Officers:** Geoffrey P. Talbot (Chair, Pres., CEO & CFO); Peter J. Upfold (Vice Chair, CTO, Sec. & Treas.); Kevin R. Harris (COO); Leonard Silverman, Ph.D. (Dir.); Robert B. Fields (Dir.)

**Auditor:** Marcum & Kliegman LLP

**Securities:** Common Stock-Symbol STCA.OB; OTC BB;  
14,886,932 common shares outstanding as of February 9, 2007.

[Return to top](#)

***Prospector  
Profile  
07.0306***

**Stoney Creek Technologies LLC**

3300 West 4th Street  
Trainer, PA 19061  
(877) 367-7224

NAICS

325000

**Category:** Bankruptcy

**Event:** Stoney Creek Technologies LLC filed for Chapter 11 protection on February 22, 2007, with the U.S. Bankruptcy Court for the Eastern District of Pennsylvania (Philadelphia), case number 07-11085, before Judge Diane W. Sigmund.

**Intellectual Property:** The Company markets multi-functional materials under the trademark SACI®, which stands for Severe Atmospheric Corrosion Inhibitor. Patented over 30 years ago, thixotropic overbased calcium sulfonate corrosion inhibitors are widely used in industry to protect metal surfaces from corrosion. [Company Website]

**Description:** The Company produces specialty chemicals that are globally marketed.

**Attorneys:** Paul Brinton Maschmeyer, Esq. and Robert W. Seitzer, Esq. of Maschmeyer Karalis P.C.; Philadelphia, PA; (215) 546-4500

**Notes:** The Company listed estimated assets and debt of \$1 million to \$100 million when it filed for bankruptcy.

[Return to top](#)



**Prospector  
Profile  
07.0307**

**Sweet Success Enterprises, Inc.**

1250 NE Loop 410, Suite 630  
San Antonio, TX 78209  
(210) 824-2496

NAICS		312100
Employees		11
Revenue	(mil)	\$0.10
Income	(mil)	(\$6.99)
Assets	(mil)	\$2.14
Liability	(mil)	\$9.62
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** PMB Helin Donovan, LLP raised doubts on Sweet Success Enterprises, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has incurred net losses since inception of \$13.3 million. The Company's continued existence is dependent upon its ability to secure adequate financing for the funding of future operations as well as its ability to achieve profitable operations.

**Intellectual Property:** The Company relies on a combination of common law trademark rights, U.S. federal registration rights and trade secret laws to protect its brand name and product formulations. Nevertheless, the Company's formulations are not patented and may be duplicated by competitors. The Company protects product formulations by confidentiality agreements with employees and contract manufacturers. [SEC Filing 10-KSB 02-14-07]

**Description:** The Company engages in the production, distribution, and marketing of ready-to-drink functional health beverages in the United States.

**Officers:** William J. Gallagher (CEO, CFO & Dir.); Glenn Williamson (Pres. & Dir.); Michael K. Launer (SVP-Sales); Graydon Webb (Dir.); Robert Lippincott (Dir.); Theodore M. Heesch (Dir.); James Haworth (Dir.); Alicia Smith Kriese (Dir.); Robert D. Straus (Dir.)

**Auditor:** PMB Helin Donovan, LLP

**Securities:** Common Stock-Symbol SWTS.OB; OTC BB;  
15,302,545 common shares outstanding as of February 8, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0308**

**Telegen Corporation**

1840 Gateway Drive Suite 200  
San Mateo, CA 94404  
(650) 292-9658

NAICS 335120

Revenue	(mil)	\$0.00
Income	(mil)	(\$0.72)
Assets	(mil)	\$0.30
Liability	(mil)	\$0.34

(for the year ended 12/31/2006)

**Category:** Audit Concerns

**Event:** Peterson Sullivan PLLC expressed doubt about Telegen Corporation's ability to continue as a going concern after auditing the Company's financial statements. The auditor points out that the Company incurred a net loss of \$723,870, and it had negative cash flows from operations of \$487,891 in fiscal year 2006. In addition, the Company had an accumulated deficit of \$45,422,233 at December 31, 2006.

**Intellectual Property:** The Company has filed two U.S. patent applications on its proprietary lighting technology. The Company expects to file a third patent application in the first quarter of 2007 and for additional patent protection as appropriate. In addition, the Company currently has one issued U.S. patent on its flat panel display technology. [SEC Filing 10-KSB 02-23-07]

**Description:** The Company is engaged in the research and development of lighting technology.

**Officers:** Duncan Troy (Chair); Richard N. Herring (CEO & Dir.); Matthew Devries (CFO); Richard G. Sellers (Sec., COO & Dir.); Mark Weber (Dir.); Charles Hunt (Dir.); Jessica L. Stevens (Dir.); Bonnie A. Crystal (Dir.)

**Auditor:** Peterson Sullivan PLLC

**Securities:** Common Stock-Symbol TEGN.PK; PNK;  
47,830,683 common shares outstanding as of February 21, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0309**

**TenFold Corporation**

698 West 10000 South  
South Jordan, UT 84095  
(801) 495-1010

NAICS		511110
Employees		46
Revenue	(mil)	\$5.00
Income	(mil)	(\$5.18)
Assets	(mil)	\$4.68
Liability	(mil)	\$2.78
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Tanner LC expressed doubts on Tenfold Corporation's ability to continue as a going concern after auditing its financial statements. The auditor explains that the Company has used significant balances of its cash in operating activities and, at present levels of cash consumption, will not have sufficient resources to meet operating needs.

**Intellectual Property:** The Company relies primarily on a combination of patent, copyright, trade secret and trademark laws, and nondisclosure and other contractual restrictions on copying and distribution to protect proprietary technology. The Company has received three separate patents in the United States. The first patent (US Patent # 6016394) relates to EnterpriseTenFold. The second (US Patent # 6061643) relates to TenFold AutoTest, its automated testing technology. The third patent (US Patent # 6301701) relates to its computer-assisted testing of software application components. The Company has these patents issued and pending in other countries. The Company's trademark portfolio contains a variety of U.S. and international trademark registrations and pending trademark applications. [SEC Filing 10-K 03-31-06]

**Description:** The Company provides services and technology for building Service Oriented Architecture-compliant applications.

**Officers:** Robert Felton (Chair, Pres. & CEO); Alexei Chadovich (SVP-R&D); Samer Diab (VP); Robert Hughes (CFO); Robert Trounce (VP); Jeffrey Walker (EVP, CTO & Dir.); Sally White (VP); Stephen Coltrin (Dir.); Robert E. Parsons, Jr. (Dir.); Ralph W. Hardy, Jr. (Dir.)

**Auditor:** Tanner LC

**Securities:** Common Stock-Symbol TENF.OB; OTC BB;  
46,557,745 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0310**

**Univec, Inc.**

822 Guilford Avenue, Suite 208  
Baltimore, MD 21202  
(410) 347-9959

NAICS		339112
Employees		4
Revenue	(mil)	\$0.08
Income	(mil)	(\$1.89)
Assets	(mil)	\$0.95
Liability	(mil)	\$5.81

(for the year ended 12/31/2005)

**Category:** Audit Concerns

**Event:** Abrams, Foster, Nole & Williams, P.A. expressed doubt on Univec, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor noted that the Company has suffered from recurring losses from operations, has negative working capital, has a total stockholders' deficit and is in default on certain debt.

**Intellectual Property:** The Company was granted a United States patent for a plunger design which, in conjunction with its patented locking clip, results in a narrow barrel, difficult-to-reuse syringe that allows for aspiration during use. The Company has filed patent applications for its locking clip and aspirating plunger in certain foreign countries participating in the Patent Cooperation Treaty. The Company has registered trademarks UNIVEC®, and Rx Ultra®, Rx Plus, The Univec Crest and the symbol representing no second use with the United States Patent and Trademark Office. [SEC Filing 10-KSB 02-23-07]

**Description:** The Company, together with its subsidiaries, produces, licenses, and markets medical products in the United States and internationally.

**Officers:** S. Robert Grass (Chair); Dr. David Dalton (Pres., CEO & Dir.); Raphael Langford (EVP & COO); Michael Lesisko (Sec., Treas. & CFO); William Wooldridge (Dir.)

**Auditor:** Abrams, Foster, Nole & Williams, P.A.

**Securities:** Common Stock-Symbol UNVC.PK; PNK;  
63,440,360 common shares outstanding as of November 10, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0311**

**US Biodefense, Inc.**

13674 E Valley Boulevard  
City Of Industry, CA 91746  
(626) 961-0562

NAICS 541710

Revenue	(mil)	\$0.16
Income	(mil)	(\$0.05)
Assets	(mil)	\$0.21
Liability	(mil)	\$0.22

(for the year ended 11/30/2005)

**Category:** Audit Concerns

**Event:** E. Randall Gruber, CPA, PC raised doubts on US Biodefense, Inc.'s ability to continue as a going concern because the Company has no established source of revenue.

**Intellectual Property:** On February 28, 2005, the Company launched T2X.us, a High Tech Transfer Search Engine, which is developing a search engine identifying intellectual property modeling the functionality of general portal search engines. On May 10, 2005, the Company entered into an agreement with the University of Texas MD Anderson Cancer Center for the priority option to review and license the patent pending technology entitled "Use of Non-marrow Stem Cell for Cardiac Regeneration." On May 11, 2005, the Company entered into a 24-month patent listing and technology transfer alliance agreement with Diamond I, Inc., a developer of wireless handheld gaming products. [SEC Filing 10-KSB 02-20-07]

**Description:** The Company focuses on the manufacture and commercialization of homeland security and biodefense products in the United States.

**Officers:** David Chin (Pres., Treas. & Dir.); Cyndi Chen (Sec. & Dir.); Marcia Marcus (Dir.)

**Auditor:** E. Randall Gruber, CPA, PC

**Securities:** Common Stock-Symbol UBDE.OB; OTC BB;  
39,059,047 common shares outstanding as of August 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0312**

**Yacht Finders, Inc.**

2045 Kettner Blvd, Ste 101  
San Diego, CA 92101  
(619) 232-1001

NAICS		454112
Revenue	(mil)	\$0.00
Income	(mil)	(\$0.01)
Assets	(mil)	\$0.02
Liability	(mil)	\$0.02
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Cordovano & Honeck LLP expressed doubt on Yacht Finders, Inc.'s ability to continue as a going concern due to its operating losses since inception.

**Intellectual Property:** The Company has secured its Internet domain name [www.yachtfindersguide.com](http://www.yachtfindersguide.com). The Company is considering filing for copyright protection of its software, but has not taken steps to file for copyright protection. [SEC Filing 10-KSB 02-15-07]

**Description:** The Company intends to create an online database for public buyers and yacht brokers to interface immediately with each other while capturing the benefits of targeting a larger market.

**Officers:** Geoffrey L. Greenwood (Pres., Sec., Treas. & Dir.)

**Auditor:** Cordovano & Honeck LLP

**Securities:** 5,179,000 common shares outstanding as of December 31, 2006.

[Return to top](#)